A new report from The Commonwealth Fund has found similarities between premium costs for marketplace enrollees and those with employer plans. According to Are Marketplace Plans Affordable?, 60% of marketplace enrollees and 55% of individuals with employer plans pay either nothing or less than $125 a month for individual coverage.
A new report from The Commonwealth Fund has found similarities between premium costs for marketplace enrollees and those with employer plans. According to Are Marketplace Plans Affordable?, 60% of marketplace enrollees and 55% of individuals with employer plans pay either nothing or less than $125 a month for individual coverage.
Marketplace enrollees eligible for a premium subsidy do not pay the full premium amount out of their own pockets, which is akin to how most employers pay part of the employees' premiums, according to Commonwealth. And yet, people with employer coverage still perceive their own health insurance as being more affordable. More than three-fourths of this group said it was very or somewhat easy to afford their premiums, but only 53% of those with marketplace coverage said the same.
“The survey findings suggest that the Affordable Care Act’s premium subsidies have been effective in making the cost of marketplace coverage similar to that of employer plans for people who have been most at risk of being uninsured,” Sara Collins, lead author of the report and vice president for Health Care Coverage and Access at The Commonwealth Fund, said in a statement. “But many marketplace enrollees report high deductibles.”
Adults with coverage through the marketplace were more likely to have per person deductibles of at least $1000 with differences larger among those with higher incomes: 53% of this group with marketplace plans had high deductibles compared to just 35% of those with employer plans.
While majorities in both groups expressed confidence in their ability to pay for care if they became sick, those with ermployer plans were more confident (80%) compared with marketplace enrollees (65%). Adults with health problems in marketplace plans were less confident than those with health problems in employer plans, but people with higher deductibles in both employer and marketplace plans were less confident they couold afford necessary care compared with those who had lower deductibles.
According to The Commonwealth Fund, the growing use and size of deductibles in both employer and marketplace plans could undermine gains in health coverage.
"In an economy that is still struggling to deliver significant wage gains to working families, ever higher cost-sharing in health plans will further degrade their financial security," the report concluded.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Solving the Transition Conundrum as More Children With Muscular Dystrophy Live to Adulthood
March 17th 2025Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach adulthood thanks to transformative therapy advances.
Read More
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Solving the Transition Conundrum as More Children With Muscular Dystrophy Live to Adulthood
March 17th 2025Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach adulthood thanks to transformative therapy advances.
Read More
2 Commerce Drive
Cranbury, NJ 08512